Resolute zotarolimus-eluting stents and Xience V everolimus-eluting stents had similar 2-year target vessel failure rates (10.8% vs. 11.6%, p=0.65) after strict DAPT discontinuation at 12 months.
RCT (n=1,391)
1:1
Does zotarolimus-eluting stent compared to everolimus-eluting stent improve target vessel failure in real-world patients following strict discontinuation of DAPT after 12 months?
Zotarolimus-eluting and everolimus-eluting stents demonstrate similar 2-year safety and efficacy in complex real-world patients following strict DAPT discontinuation at 12 months.
Absolute Event Rate: 10.8% vs 11.6%
p-value: p=0.65
Objectives: The aim of this study was to assess the safety and efficacy of the implantation of Resolute zotarolimus-eluting stents (ZES) (Medtronic Inc., Santa Rosa, California) and Xience V everolimus-eluting stents (EES) (Abbott Vascular, Santa Clara, California) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months.Background: Only limited long-term follow-up data are available from head-to-head comparisons of second-generation drug-eluting stents.Methods: The randomized TWENTE (The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente) trial is an investigator-initiated study performed in a population with many complex patients and lesions and only limited exclusion criteria. Patients were randomly assigned 1:1 to ZES (n = 697) or EES (n = 694).Results: Two-year follow-up information was available on all patients. The rate of continuation of DAPT beyond 12 months was very low (5.4%). The primary endpoint of target vessel failure, a composite of cardiac death, target vessel–related myocardial infarction, and target vessel revascularization, did not differ between ZES and EES (10.8% vs. 11.6, p = 0.65), despite fewer target lesion revascularizations in patients with EES (2.6% vs. 4.9%, p = 0.03). The patient-oriented composite endpoint was similar (16.4% vs. 17.1%, p = 0.75). Two-year rates of definite or probable stent thrombosis were 1.2% and 1.4%, respectively (p = 0.63). Very late definite or probable stent thrombosis occurred only in 2 patients in each study arm (0.3% vs. 0.3%, p = 1.00).Conclusions: After 2 years of follow-up and stringent discontinuation of DAPT beyond 12 months, Resolute ZES and Xience V EES showed similar results in terms of safety and efficacy for treating patients with a majority of complex lesions and off-label indications for drug-eluting stents. (The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente
Tandjung et al. (Wed,) conducted a rct in Coronary artery disease requiring drug-eluting stents (n=1,391). Resolute zotarolimus-eluting stents (ZES) vs. Xience V everolimus-eluting stents (EES) was evaluated on Target vessel failure, a composite of cardiac death, target vessel-related myocardial infarction, and target vessel revascularization (p=0.65). Resolute zotarolimus-eluting stents and Xience V everolimus-eluting stents had similar 2-year target vessel failure rates (10.8% vs. 11.6%, p=0.65) after strict DAPT discontinuation at 12 months.